In pharmacology, this is called delayed gastric emptying
As the first dual GIP/GLP-1 receptor agonist, tirzepatide represents a significant advancement in metabolic therapeutics, offering enhanced efficacy compared to single-pathway agents
The following have been previously described: vps29 20 , snx1 51 , snx2a 51 , snx2b 51 , vps9a 57 , mon1-2 45 , ccz1a 58 , ccz1b 58 , vps35a-1b-2c-1 7 , vps35b-1c-1 7 , GFP-VSR1 59 , VPS29-GFP 20 , SNX1-GFP/Ch 8 , mRFP-SYP32 (WAVE22) 60 , Ch-RAB5 (WAVE7) 60 , Ch-RAB7 (WAVE5) 60 , VHA-a1-mRFP 61 , mCIT-PH OSBP (P7Y) 62
Some patients also experience mild dry mouth, which concentrates minerals on the tongue and amplifies metallic sensations